Treatment strategies for myelodysplastic syndrome in 2021
Authors:
Petra Bělohlávková
Authors‘ workplace:
IV. interní hematologická klinika, LF UK a FN Hradec Králové
Published in:
Vnitř Lék 2021; 67(3): 150-155
Category:
Review Articles
Overview
The heterogeneous nature of myelodysplastic syndrome (MDS) brings a very variable prognosis of patients with the need for individualized treatment. The prognosis and treatment depend on the conventional determination of IPSS (International Prognostic Scoring System) and its revised form IPSS-R, which divides patients into lower and higher risk groups. Treatment of patients with lower risk of MDS include the improvement of cytopenia, especially anemia. The goal of treatment in patients with higher risk of MDS is delaying disease progression and improve patient survival. The only curative method for therapy of MDS is allogeneic hematopoietic stem cell transplantation (HSCT), howewer it is rarely applicable due to the age and comorbidities of patients.
Keywords:
azacitidin – erythropoiesis-stimulating agents – myelodysplastic syndromes – lenalidomide – treatment
Sources
1. Malcovati L, Hellström-Lindberg E, Bowen D et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European Leukemia- Net, Blood. 2013; 122: 2943–2964.
2. Arber DA, Orazi A, Hasserjian R et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127: 2391–2405.
3. Greenberg PL, Tuechler H, Schanz J et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012; 120: 2454–2465.
4. Platzbecker U. Treatment of MDS. Blood. 2019; 7: 133(10): 1096–1107.
5. Fenaux P, Platzbecker U, Ades L. How we manage adults with myelodysplastic syndrome. Br J Haematol. 2019. doi: 10.1111/bjh.16206.
6. Gascón P, Krendyukov A, Mathieson N, Aapro M. Epoetin Alfa for the Treatment of Myelodysplastic Syndrome-Related Anemia: A Review of Clinical Data, Clinical Guidelines, and Treatment Protocols. Leuk Res. 2019; 81: 35–42.
7. Komrokji RS, List AF. Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes. Ann Oncol. 2016; 27: 62–68.
8. Jonášová A, Červinek L, Bělohlávková P et al. První české zkušenosti s lenalidomidem v terapii anemických nemocných s myelodysplastickým syndromem s delecí dlouhého ramene 5. chromozomu, Vnitr Lek. 2015; 61(12): 1028–1033.
9. Santini V, Almeida A, Giagounidis A et al. Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents. J. Clin. Oncol. 2016; 34: 2988–2996.
10. Kantarjian HM, Fenaux P, Sekeres MA et al. Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. Lancet Haematol. 2018; 5: e117–26.10.
11. Langemeijer S, De Swart L, Yu G, Smith A, Crouch S, Johnston T et al. Impact of treatment with iron chelators in lower-risk MDS patients participating in the European leukemianet MDS (EUMDS) registry. Blood. 2016; 128(22): 3186.
12. Gattermann N. Do Recent Randomized Trial Results Influence which Patients with Myelodysplastic Syndromes Receive Iron Chelation? Hematol Oncol Clin North Am. 2020; 34(2): 465–473.
13. Stahl M, Bewersdorf JP, Giri S et al. Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis Haematologica 2020; 105(1): 102–111.
14. de Witte T, Bowen D, Robin M et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. 2017; 129(13): 1753–1762.
15. Zeidan AM, Stahl M, DeVeaux M, Giri S, Huntington S, Podoltsev N et al. Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates? Blood Cancer J; 2018; 8: 55.
16. Fenaux P. The Medalist Trial: results of a phase 3, randomized, double-blind, placebocontrolled study of luspatercept to treat anemia in patients with very low-, low-, or intermediate- risk myelodysplastic syndromes (MDS) with ring sideroblasts (RS) who require red blood cell (RBC) transfusions. Blood. 2018; 132(Suppl 1): 1.
17. Platzbecker U, Germing U, Götze KS et al. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open- -label phase 2 dose-finding study with long-term extension study. Lancet Oncol. 2017; 18: 1338–1347.
18. Steensma DP, Platzbecker U, Van Eygen K et al. Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive. Blood. 2018; 132: 463.
19. Fenaux P, Raza A, Vellenga E, Platzbecker U, Santini V, Samarina I. Efficacy and Safety of Imetelstat in RBC Transfusion-Dependent (TD) IPSS Low/Int-1 MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agents (ESA) (IMerge). Blood. 2017; 130: 4256.
20. Yang Y, Yu X, Zhang Y et al. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against cisplatin-induced acute kidney injury. Clin. Sci. 2018; 132: 825–838.
21. Henry JG, Glaspy J, Harrup RA et al. Roxadustat (FG4592; ASP1517; AZD9941) in the Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (LR-MDS) and Low Red Blood Cell (RBC) Transfusion Burden (LTB). Blood. 2019; 134. (Supplement 1)
22. Sekeres MA, Othus M, List AF et al. Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG s1117. J Clin Oncol. 2017; 35(24): 2745–2753.
23. Dickinson M, Honar Cherif H, Fenaux P et al. Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia. Blood. 2018; 132: 2629–2638.
24. Sekeres MA, Watts J, Radinof A et al. Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML. Leukemia. 2021 Jan 22. doi: 10.1038/s41375-021-01125-4. Online ahead of print.
25. Wei AH, Strickland SA Jr, Hou JZ et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study. J Clin Oncol 2019; 37: 1277–1284.
26. Garcia-Manero G, Roboz G, Walsh K et al. Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. Lancet Hematol. 2019; 6: 317–327.
27. Navada SC, Garcia-Manero G, Atallah EL et al. Phase II study of oral rigosertib combined with azacitidine (AZA) as first line therapy in patients (Pts) with higher-risk myelodysplastic syndromes (HR-MDSt]. American Society of Hematology. 2019. http:// dx.doi. org/10.1182/blood-2019-131676.
28. DiNardo CD, Watts JM, Stein EM, de Botton S, Fathi AT, Prince GT et al. Ivosidenib (AG- 120) induced durable remissions and transfusion independence in patients with IDH- 1-mutant relapsed or refractory myelodysplastic syndrome: results from a phase 1 dose escalation and expansion study. Blood. 2018; 132: 1812.
29. Sallman DA, DeZern AE, Garcia-Manero G et al. Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML). Blood. 2019; 134(Supplement 1): 676–676.
Labels
Diabetology Endocrinology Internal medicine Haematology General practitioner for adultsArticle was published in
Internal Medicine
2021 Issue 3
Most read in this issue
- What's new in the 2020 update of the CEAP classification system of chronic venous disease?
- Vericiguat in patients with heart failure and reduced ejection fraction
- The use of moxonidine in the treatment of arterial hypertension
- Treatment strategies for myelodysplastic syndrome in 2021